Denali Therapeutics registers Phase 1/1b trial of DNL921 in Alzheimer's disease
Denali's new placebo-controlled study will test single and multiple doses of DNL921 in healthy volunteers and Alzheimer's patients, with results expected in 2030.
Denali Therapeutics had one clinical trial update listed this week.
- DNL921 is entering a Phase 1/1b, randomized, placebo-controlled, double-blind trial sponsored by Denali Therapeutics, evaluating single and multiple doses of the drug in healthy participants and participants with Alzheimer's disease, measuring safety, tolerability, pharmacokinetics, and pharmacodynamics.1 The study is listed as recruiting, with an actual start date of 2026-08-07 and estimated enrollment of 178 participants.1 Primary and study completion are estimated for 2030-04, according to the registry record.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.